fbpx

Nyheder

Lundbeckfonden Ventures nyheder

  ‘OCTAVE’ Study Will AssessColoAd1in Patients with Ovarian Cancer   PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent...
  Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it has entered into an exclusive distribution agreement with Chiesi Farmaceutici S.p.A, a fully integrated European Pharmaceutical company focused on respiratory disease and special care products, for the commercialization and distribution of its novel formulation immunosuppressant drug candidate LCP-Tacro in certain countries, including Europe, Turkey and...
Agreement will support future clinical trials of Celladon’s product candidate MYDICAR® for the treatment of advanced heart failure.   Lonza, a global leader in the field of viral therapy manufacturing, and Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that they have entered into...
Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces positive results from its Phase IIa proof-of-concept study investigating APD403 for the prevention of acute nausea & vomiting in cancer patients receiving the highly emetogenic chemotherapy drug cisplatin. Although a number of anti-emetics are available on the market, these...
‘Evolve’ Study Will Assess Safety and Tolerability of Unique Anti-Cancer Agent, ColoAd1   (PsiOxus) has treated the first patient in its phase I/II clinical trial of ColoAd1 for the treatment of metastatic solid tumours. The Evolve (EValuating OncoLytic Vaccine Efficacy) study is the first clinical trial of the systemically available oncolytic vaccine ColoAd1, a highly...
  Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that FierceBiotech named Celladon as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection.   “You don't...
Agreement Covers Distribution Rights of CERAMENT in United States and Canada BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the signing of a multi-year exclusive distribution agreement with Biomet, Inc., a global leader in the manufacture of musculoskeletal medical products. Under...
– 200-Subject Trial of Novel Cell Therapy AC607 at leading tertiary care centers in the United States AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company’s mesenchymal stem cell therapy, as a potential treatment for acute kidney injury (AKI). The randomized, double-blind, placebo-controlled, multicenter trial, designated ACT-AKI...
Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first patient in a Phase 2b clinical trial of MYDICAR, Celladon’s first in class therapeutic for the treatment of advanced heart failure (HF). Chronic HF is a leading cause of hospitalization and...
1 58 59 60 61 62 65

Lundbeckfonden Ventures

Nyheder

scPharmaceuticals Announces FUROSCIX® NDA Resubmission
3. juli 2020
Acacia Pharma Group PLC – Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedatio
3. juli 2020
Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline
26. juni 2020